5.09
Myriad Genetics Inc stock is traded at $5.09, with a volume of 1.69M.
It is up +3.46% in the last 24 hours and down -29.99% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$4.92
Open:
$4.93
24h Volume:
1.69M
Relative Volume:
0.83
Market Cap:
$386.22M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-3.9154
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
+21.48%
1M Performance:
-29.99%
6M Performance:
-66.36%
1Y Performance:
-77.17%
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MYGN
Myriad Genetics Inc
|
5.09 | 386.22M | 823.60M | -116.00M | -107.30M | -1.30 |
![]()
TMO
Thermo Fisher Scientific Inc
|
401.90 | 152.06B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
196.02 | 135.91B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
524.91 | 41.29B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
115.80 | 31.79B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
152.32 | 24.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
Feb-12-25 | Initiated | Craig Hallum | Buy |
Dec-10-24 | Initiated | UBS | Neutral |
Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
Aug-28-24 | Initiated | Wells Fargo | Overweight |
Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
Jun-03-24 | Resumed | Jefferies | Underperform |
May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Dec-21-23 | Resumed | Piper Sandler | Neutral |
Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
Dec-14-23 | Initiated | Guggenheim | Buy |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Jul-05-23 | Resumed | JP Morgan | Underweight |
May-23-23 | Upgrade | Goldman | Sell → Buy |
Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Oct-06-22 | Initiated | Stephens | Equal-Weight |
Oct-15-21 | Resumed | Cowen | Market Perform |
Jun-15-21 | Initiated | Raymond James | Mkt Perform |
Jun-03-21 | Initiated | Goldman | Sell |
Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
Mar-12-19 | Reiterated | Needham | Strong Buy |
Jan-03-19 | Initiated | Needham | Strong Buy |
Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Jan-29-18 | Initiated | Goldman | Sell |
Jan-22-18 | Reiterated | Barclays | Equal Weight |
Jan-05-18 | Initiated | BTIG Research | Buy |
Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
Aug-09-17 | Reiterated | Barclays | Equal Weight |
Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
Jan-18-17 | Initiated | Deutsche Bank | Sell |
Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
3 Reasons to Avoid MYGN and 1 Stock to Buy Instead - FinancialContent
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen - GlobeNewswire
FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow - ACCESS Newswire
Trend Tracker for (MYGN) - news.stocktradersdaily.com
US Direct-To-Consumer Genetic Testing Market Report 2025, - GlobeNewswire
US Direct-To-Consumer Genetic Testing Market Report 2025, Competitive Analysis of 23andMe, Gene by Gene, Ancestry, Genesis, EasyDNA, Veritas, Myriad Genetics, Taconic Biosciences, & Color Health - Yahoo
Myriad Genetics (MYGN) Launches FirstGene Multiple Prenatal Screen | MYGN Stock News - GuruFocus
Myriad Genetics Launches FirstGene™ Prenatal Screen for Comprehensive Genetic Risk Assessment in One Blood Draw - Nasdaq
Breakthrough Prenatal Screen Combines 4 Tests in 1 Blood DrawNo Father Sample Needed - Stock Titan
Hereditary Testing MarketGlobal Industry Trends, - GlobeNewswire
MYGN INVESTOR REMINDER: Hagens Berman Reminds Myriad Genetics (MYGN) Investors of Securities Fraud Lawsuit, Encourages Investors Who Lost $50,000+ to Contact the Firm - ACCESS Newswire
Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - GlobeNewswire
Myriad Genetics Reports Ultra-Sensitive CtDNA Detection With Precise MRD In Pan-Cancer Study - Nasdaq
Myriad Genetics (MYGN) Reports Promising Results from MONSTAR-SCREEN 3 Study | MYGN Stock News - GuruFocus
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types - GlobeNewswire
Breakthrough: Myriad Genetics New Cancer Test Detects Tumors 60% Better Than First-Gen Tests - Stock Titan
Ameriprise Financial Inc. Has $2.88 Million Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025 - Insider Monkey
Myriad Genetics Highlights New Research Advancements and Oncolog - GuruFocus
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting | MYGN Stock News - GuruFocus
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting - GlobeNewswire
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Man Group plc Makes New $390,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire
Deutsche Bank AG Purchases 27,541 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out - ACCESS Newswire
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud - ACCESS Newswire
Trading (MYGN) With Integrated Risk Controls - news.stocktradersdaily.com
ATTENTION MYGN Shareholders: Lost Money on Myriad Genetics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Scotiabank Downgrades Myriad Genetics (NASDAQ:MYGN) to Sector Perform - Defense World
Microtomes Market Generated Opportunities, Future Scope - openPR.com
Parp Inhibitor Biomarkers Market Generated Opportunities, - openPR.com
BNP Paribas Financial Markets Purchases 23,408 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Captrust Financial Advisors Grows Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Myriad Genetics Shares Fall After Downgrade From Scotiabank - marketscreener.com
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Genetic Counseling Market Deep Research Report with Forecast by 2032 | Invitae Corporation, Myriad Genetics - openPR.com
Myriad Genetics (MYGN) Faces Downgrade and Price Target Reduction | MYGN Stock News - GuruFocus
This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Scotiabank Downgrades Myriad Genetics (MYGN) With Revised Price - GuruFocus
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Scotiabank Downgrades Myriad Genetics (MYGN) Rating | MYGN Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect - ACCESS Newswire
Myriad Genetics (MYGN) Faces Downgrade Amidst Challenging Quarte - GuruFocus
Myriad Genetics (MYGN) Faces Price Target Cut After Q1 Miss | MY - GuruFocus
Levi & Korsinsky Investigates Possible Securities Fraud by Myriad Genetics, Inc. (MYGN) - ACCESS Newswire
Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating - marketscreener.com
MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp - Yahoo Finance
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):